Home/Pipeline/Nasefrin

Nasefrin

Anaphylaxis

PreclinicalActive

Key Facts

Indication

Anaphylaxis

Phase

Preclinical

Status

Active

Company

Noveeda

About Noveeda

Noveeda is a private, pre-revenue biopharma company developing a pipeline of needle-free emergency medicines. Its lead product, Nasefrin, is an intranasal epinephrine formulation for anaphylaxis, currently in preclinical development with key milestones targeted for 2025-2027. The company combines an experienced international executive team with a scientific R&D center in Czechia to advance its portfolio targeting conditions like poisoning, seizures, and hypoglycemia.

View full company profile

Therapeutic Areas

Allergy & Immunology Toxicology Neurology Endocrinology

Other Anaphylaxis Drugs

Drug	Company	Phase	Status
Epinephrine/Adrenaline Alginate Film	Klaria	Pre-clinical/Development	Active
Epinephrine Auto-Injector	Viatris	Filed	Pending Approval
SYMJEPI	Assertio Holdings	Approved	Marketed